Phase I Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer
Vascular endothelial growth factor receptor 1 and 2 (VEGFR1 andVEGFR2) are essential targets
to tumor angiogenesis, and we identified that peptides derived from these receptors
significantly induce the effective tumor specific CTL response in vitro and in vivo.
According to these findings, in this trial, we evaluate the safety, tolerability and immune
response of these peptide emulsified with Montanide ISA 51 in combination with gemcitabine
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Adverse effect, toxicities as assessed by NCI CTCAE version3.0
3 months
Yes
Mitsukazu Gotoh, MD, PhD
Study Chair
Fukushima Medical University, First depertment of Surgery
Japan: Ministry of Health, Labor and Welfare
FPCR1R2-1
NCT00639925
March 2007
March 2013
Name | Location |
---|